We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+34.6%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$555M
AUM Growth
-$203M
Cap. Flow
-$287M
Cap. Flow %
-51.67%
Top 10 Hldgs %
64.54%
Holding
90
New
25
Increased
22
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
THER
THERATECHNOLOGIES INC COM
THER
+$26.9M
2
KRYS icon
Krystal Biotech
KRYS
+$11.4M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.8M
4
AZN icon
AstraZeneca
AZN
+$9.76M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.78M

Top Sells

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$10.2M
2
VCEL icon
Vericel Corp
VCEL
+$7.3M
3
EPIX
ESSA Pharma
EPIX
+$7.1M
4
MRSN
Mersana Therapeutics
MRSN
+$5.5M
5
DRIO icon
DarioHealth
DRIO
+$5.02M

Sector Composition

Rank Sector Weight
1 Healthcare 90.73%
2 Consumer Staples 1.79%
3 Real Estate 0.62%
4 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
51
STAAR Surgical
STAA
$1.15B
$1.76M 0.32%
16,700
+13,400
+406% +$1.34M
CMPS
52
Compass Pathways
CMPS
$1.83B
$1.57M 0.28%
42,743
– –
IMDX
53
Insight Molecular Diagnostics
IMDX
$155M
$1.54M 0.28%
+14,850
New +$1.41M
OSH
54
DELISTED
Oak Street Health, Inc.
OSH
$1.5M 0.27%
27,612
– –
CMAX
55
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$1.44M 0.26%
+3,963
New +$1.67M
MORF
56
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.36M 0.25%
+21,500
New +$987K
SRRK icon
57
Scholar Rock
SRRK
$6.41B
$1.32M 0.24%
26,101
+1,617
+7% +$89.5K
KDMN
58
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.31M 0.24%
336,442
– –
PVLA
59
Palvella Therapeutics
PVLA
$2.23B
$1.28M 0.23%
6,250
– –
DNTH icon
60
Dianthus Therapeutics
DNTH
$6.15B
$1.18M 0.21%
+6,250
New +$1.05M
VRDN icon
61
Viridian Therapeutics
VRDN
$2.55B
$1.13M 0.2%
67,685
-13,500
-17% -$253K
TRIL
62
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.11M 0.2%
103,819
– –
KYMR icon
63
Kymera Therapeutics
KYMR
$8.85B
$1.09M 0.2%
28,116
+15,000
+114% +$903K
ADVM
64
DELISTED
Adverum Biotechnologies
ADVM
$986K 0.18%
9,999
-3,600
-26% -$432K
ONCR
65
DELISTED
Oncorus, Inc.
ONCR
$929K 0.17%
66,722
+10,300
+18% +$213K
RVNC
66
DELISTED
Revance Therapeutics, Inc.
RVNC
$870K 0.16%
31,136
– –
MRTX
67
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$594K 0.11%
3,466
-4,372
-56% -$866K
TPTX
68
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$528K 0.1%
5,577
-13,436
-71% -$1.6M
HIMS.WS
69
DELISTED
Hims & Hers Health, Inc. Warrants, each whole warrant exercisable for one Class A Common Stock at an
HIMS.WS
$404K 0.07%
+91,793
New +$599K
CRDF icon
70
Cardiff Oncology
CRDF
$74.7M
$395K 0.07%
42,684
-14,225
-25% -$173K
ABBV icon
71
AbbVie
ABBV
$431B
– –
-21,477
Closed -$2.3M
AXGN icon
72
Axogen
AXGN
$2.38B
– –
-33,813
Closed -$605K
BIIB icon
73
Biogen
BIIB
$30.5B
– –
-3,899
Closed -$955K
CRSP icon
74
CRISPR Therapeutics
CRSP
$4.99B
– –
-10,825
Closed -$1.66M
FATE icon
75
Fate Therapeutics
FATE
$290M
– –
-6,830
Closed -$621K
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Soleus Capital Management held 90 positions worth $555M, down 27% from $758M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Soleus Capital Management withdrew a net $287M in Q1 2021, closing 18 positions and reducing 13 holdings. Its most notable exit was Invitae Corporation, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 44% a quarter earlier, followed by Consumer Staples and Real Estate.

Against the trend, Soleus Capital Management opened a new position in THERATECHNOLOGIES INC COM worth $26.9M.

  • Soleus Capital Management's largest Q1 2021 buy was THERATECHNOLOGIES INC COM: 6,951,347 shares worth $26.9M.
  • Soleus Capital Management added most to Krystal Biotech in Q1 2021, an estimated $11.4M increase.
  • Soleus Capital Management's biggest Q1 2021 reduction was ESSA Pharma, cutting an estimated $7.1M.
  • Soleus Capital Management fully exited Invitae Corporation in Q1 2021, selling an estimated $10.2M.
  • Soleus Capital Management's ten largest holdings make up 65% of its $555M portfolio in Q1 2021.
  • Soleus Capital Management opened 25 new positions and closed 18 in Q1 2021.
  • Soleus Capital Management's portfolio value fell 27% quarter-over-quarter to $555M.

Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.